Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -8 of 8
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/6/2008
 
First Published:
6/2/2006
1.
Phase II Study of Combination Chemotherapy, Radiotherapy, and/or Surgery in Patients With High-Risk Renal Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
30 and under
NCI
COG-AREN0321
AREN0321, NCT00335556
2.
Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
SCRI GU 32
AVF3673s, NCT00323739
Last Modified:
11/17/2006
 
First Published:
10/21/2006
3.
Phase II Study of Nonmyeloablative Lymphodepleting Chemotherapy Comprising Cyclophosphamide and Fludarabine Phosphate Followed By Anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes and High-Dose Aldesleukin in Patients With Metastatic Cancer That Overexpresses p53
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
NCI-07-C-0003
NCI-P6850, NCT00393029
4.
Phase 2 Study in Patients With MiT Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
13 and over
Pharmaceutical / Industry
ARQ 197-204
NCT00557609
5.
R1507 in Patients With Recurrent or Refractory Sarcomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
12 and over
Other
2007-0515
NCT00615680
Last Modified:
5/19/2008
 
First Published:
2/19/2008
6.
Phase I Study of Bortezomib and Gemcitabine in Older Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
70 and over
NCI
UMN-2006LS040
UMN-2006LS040, UMN-X05227, NCT00620295
7.
Comparison of Immune Response Following Surgical Management of Renal Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Natural history/Epidemiology, Treatment
Active
18 and over
Other
IRB3 021-2005
NCT00289146
8.
Respiratory Tumor and Normal Tissue Motion
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Natural history/Epidemiology, Treatment
Active
Not specified
Other
2003-0962
NCT00415675
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute